Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

被引：0

作者：

Eder, Lihi ^{[1
,2
]}

Selmi, Carlo ^{[3
]}

Mease, Philip ^{[4
,5
]}

Ogdie, Alexis ^{[6
]}

Nantel, Francois ^{[7
]}

Lavie, Frederic ^{[8
]}

Sharaf, Mohamed ^{[9
]}

Adelakun, Oyediran ^{[10
]}

Rampakakis, Emmanouil ^{[11
]}

Vegas, Laura Pina ^{[12
]}

Coates, Laura ^{[13
]}

机构：

[1] Univ Toronto, Womens Coll Hosp, Toronto, ON, Canada

[2] Dept Med, Toronto, ON, Canada

[3] IRCCS Ist Clin Humanitas, Rozzano, Italy

[4] Providence St Joseph, Swedish Med Ctr, Seattle, WA USA

[5] Univ Washington, Sch Med, Seattle, WA USA

[6] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA

[7] Nantel MedSci Consult, Montreal, PQ, Canada

[8] Janssen Cilag Global Med Affairs, Immunol Global Med Affairs, Issy Les Moulineaux, France

[9] Middle East FZ LLC, Johnson & Johnson, Dubai, U Arab Emirates

[10] Janssen Res Dev LLC, Titusville, NJ USA

[11] McGill Univ, Dept Pediat Sci Affairs, JSS Med Res Inc, Montreal, PQ, Canada

[12] Leiden Univ, Med Ctr, Leiden, Netherlands

[13] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2342

引用

页码：4720 / 4722

页数：3

共 50 条

[21] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Mease, Philip J.
Rahman, Proton
Gottlieb, Alice B.
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Sheng, Shihong
Agarwal, Prasheen
Zhou, Bei
Zhuang, Yanli
van der Heijde, Desiree
McInnes, Iain B.
LANCET, 2020, 395 (10230): : 1126 - 1136
[22] Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Kavanaugh, Arthur
Soriano, Enrique
Dutz, Jan
Selmi, Carlo
Rampakakis, Emmanouil
Shiff, Natalie
Nantel, Francois
Lavie, Frederic
Coates, Laura
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4421 - 4424
[23] EFFICACY AND SAFETY RESULTS OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OVER 56 WEEKS FROM A PHASE 2A, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Deodhar, A.
Gottlieb, A. B.
Boehricke, W-H.
Dong, B.
Wang, Y.
Zhuang, Y.
Barchuk, W.
Xu, X. L.
Hsia, E.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 201 - 201
[24] LONG-TERM EFFICACY OF GUSELKUMAB IN FATIGUE AND IDENTIFICATION OF EARLY TREATMENT TARGETS: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY CONDUCTED IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
Gladman, D. D.
Starr, M.
Ranza, R.
Bravo Perdomo, A. M.
Strauss, M.
Shawi, M.
Han, C.
Rampakakis, E.
Ostor, A. Andrew
Mease, P. J.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1765 - 1765
[25] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naive Patients with Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana-Maria Bravo
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip J.
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4175 - 4178
[26] The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
Christopher T. Ritchlin
Laura C. Coates
Philip J. Mease
Désirée van der Heijde
Jiao Song
Yusang Jiang
May Shawi
Alexa P. Kollmeier
Proton Rahman
Trials, 24
[27] The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
Ritchlin, Christopher T.
Coates, Laura C.
Mease, Philip J.
van der Heijde, Desiree
Song, Jiao
Jiang, Yusang
Shawi, May
Kollmeier, Alexa P.
Rahman, Proton
TRIALS, 2023, 24 (01)
[28] Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
Gladman, Dafna
Starr, Michael
Ranza, Roberto
Perdomo, Ana
Strauss, Marcie
Shawi, May
Han, Chenglong
Rampakakis, Emmanouil
Ostor, Andrew
Mease, Philip
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 79 - 79
[29] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Ritchlin, Christopher
Mease, Philip J.
Boehncke, Wolf-Henning
Tesser, John
Chakravarty, Soumya
Rampakakis, Emmanouil
Shawi, May
Schiopu, Elena
Merola, Joseph
McInnes, Iain B.
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4178 - 4182
[30] Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
Mease, P.
McInnes, I. B.
Kirkham, B.
Kavanaugh, A.
Rahman, P.
Van Der Heijde, D.
Landewe, R.
Nash, P.
Pricop, L.
Yuan, J.
Richards, H.
Mpofu, S.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S29 - S29

← 1 2 3 4 5 →